MAXLINEAR, INC. v. CF CRESPE LLC
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Dyk, Schall, and Reyna. Appeal from the Patent Trial and Appeal Board.
Summary: Final written decisions by an administrative tribunal invalidating a patent can have a preclusive effect.
MaxLinear filed an IPR petition on claims of a CF Crespe patent. The Board instituted review on the independent claims and certain dependent claims and ultimately issued a final written decision upholding the patentability of the challenged claims. However, the Board limited its analysis to the independent claims and did not separately analyze the dependent claims. MaxLinear appealed the Board’s decision of patentability.
Pending the appeal, the Board issued final written decisions for two other IPR proceedings concerning the same CF Crespe patent, but considering different prior art. In these proceedings, which were subsequently affirmed by the Federal Circuit, the Board held that certain claims of the CF Crespe patent were unpatentable including the independent claims that were held patentable in the IPR proceeding that was the subject of this appeal.
The parties agreed that the prior decisions in the other two IPR proceedings and that were upheld by the Federal Circuit had a preclusive effect in this proceeding. The Federal Circuit noted that in light of the B&B Hardware, Inc. v. Harg is Indus., Inc. decision the parties could hardly argue otherwise. Issue preclusion prevents a party from re-litigating an issue and applies in the administrative context. Accordingly, the Federal Circuit held that the decisions in the two other IPR proceedings finally resolved the issue of unpatentability of the independent claims. However, because the Board failed to separately analyze the dependent claims, the Federal Circuit remanded to the Board with instructions to consider the patentability of the dependent claims.
This case is: MAXLINEAR, INC. v. CF CRESPE LLC
Written By: Nicole R. Townes and David J. Grant
Edited By: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…